Teva Pharmaceutical Industries (TEVA) Earnings Date, Estimates & Call Transcripts $18.60 -2.93 (-13.59%) Closing price 01/29/2025 03:59 PM EasternExtended Trading$18.64 +0.04 (+0.20%) As of 01/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Teva Pharmaceutical Industries Latest Earnings SummaryLatest Q4 2024 Earnings DateJan. 29EstimatedActual EPS (Jan. 29) $0.70 Beat By $0.01 Consensus EPS (Jan. 29) $0.69 Teva Pharmaceutical Industries released Q4 2024 earnings on January 29, 2025, reporting an EPS of $0.70, which topped analysts' consensus estimates of $0.69 by $0.01. With a trailing EPS of -$0.85, Teva Pharmaceutical Industries' earnings are expected to grow 11.81% next year, from $2.37 to $2.65 per share. Conference Call Get Teva Pharmaceutical Industries Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Teva Pharmaceutical Industries and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataTEVA Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.TEVA Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Teva Pharmaceutical Industries Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20251$0.48$0.48$0.48 Q2 20251$0.59$0.59$0.59 Q3 20251$0.67$0.67$0.67 Q4 20251$0.83$0.83$0.83 FY 20254$2.57$2.57$2.57 Q1 20261$0.49$0.49$0.49 Q2 20261$0.61$0.61$0.61 Q3 20261$0.81$0.81$0.81 Teva Pharmaceutical Industries Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails1/29/2025Q4 2024$0.69$0.70+$0.01-$0.19$4.10B-7/31/2024Q2 2024$0.55$0.58+$0.03$1.91$3.99B$4.16B5/8/2024Q1 2024$0.49$0.46 -$0.03$1.04$3.70B$3.82B1/31/2024Q4 2023$0.73$0.98+$0.25$1.55$3.97B$4.46B11/8/2023Q3 2023$0.57$0.60+$0.03$1.09$3.73B$3.90B8/2/2023Q2 2023$0.52$0.54+$0.02$1.85$3.69B$3.88B5/10/2023Q1 2023$0.55$0.37 -$0.18$0.92$3.60B$3.66B2/8/2023Q4 2022$0.64$0.68+$0.04$2.46$3.90B$3.88B Teva Pharmaceutical Industries Earnings - Frequently Asked Questions When is Teva Pharmaceutical Industries's earnings date? Teva Pharmaceutical Industries has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, January 29th, 2025 based off last year's report dates. Learn more on TEVA's earnings history. What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings? Teva Pharmaceutical Industries updated its FY 2025 earnings guidance on Wednesday, January, 29th. The company provided earnings per share (EPS) guidance of 2.350-2.650 for the period, compared to the consensus EPS estimate of 2.780. The company issued revenue guidance of $16.8 billion-$17.4 billion, compared to the consensus revenue estimate of $17.1 billion. Did Teva Pharmaceutical Industries beat their earnings estimates last quarter? In the previous quarter, Teva Pharmaceutical Industries (NYSE:TEVA) reported $0.70 earnings per share (EPS) to beat the analysts' consensus estimate of $0.69 by $0.01. Learn more on analysts' earnings estimate vs. TEVA's actual earnings. How can I listen to Teva Pharmaceutical Industries's earnings conference call? The conference call for Teva Pharmaceutical Industries's latest earnings report can be listened to online. Listen to Conference Call How much revenue does Teva Pharmaceutical Industries generate each year? Teva Pharmaceutical Industries (NYSE:TEVA) has a recorded annual revenue of $16.77 billion. How much profit does Teva Pharmaceutical Industries generate each year? Teva Pharmaceutical Industries (NYSE:TEVA) has a recorded net income of -$559 million. TEVA has generated -$0.85 earnings per share over the last four quarters. What is Teva Pharmaceutical Industries's price-to-earnings ratio? Teva Pharmaceutical Industries (NYSE:TEVA) has a forward price-to-earnings ratio of 7.85. The price/earnings-to-growth ratio is 1.11. What is Teva Pharmaceutical Industries's EPS forecast for next year? Teva Pharmaceutical Industries's earnings are expected to grow from $2.37 per share to $2.65 per share in the next year, which is a 11.81% increase. More Earnings Resources from MarketBeat Related Companies GSK Earnings Results TAK Earnings Results ARGX Earnings Results BNTX Earnings Results BGNE Earnings Results SMMT Earnings Results MRNA Earnings Results GMAB Earnings Results VTRS Earnings Results ITCI Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? This page (NYSE:TEVA) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredElon’s ultimate power move?THE ELON SHOCK All of Elon Musk’s strange behavior may soon make sense… and impact the markets in a way no ...Altimetry | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredHot Stock Alert! Biotech innovator on the NYSE announces breakthrough antiviral therapyA revolutionary antiviral drug is here! This breakthrough could mean viruses are unlikely to escape treatment....Smallcaps Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Teva Pharmaceutical Industries Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Teva Pharmaceutical Industries With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
